FDA Pulls Plug on Four COVID Tests: Time to Switch
Published Date: 5/29/2025
Notice
Summary
The FDA is ending emergency use permissions for four COVID-19 test kits from Pfizer, MAWD Laboratories, and Nuclein (now part of Molecular Diagnostics). This means these specific tests can no longer be used under emergency rules, as the companies asked for it. If you use these tests, check for updates soon—this change could affect testing options but won’t cost you extra.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Four COVID-19 Tests Lose Emergency Use
If you use one of these specific COVID-19 tests, they can no longer be used under the Emergency Use Authorization rules: Lucira COVID-19 All-In-One Test Kit; Lucira CHECK-IT COVID-19 Test Kit; MAWD Laboratories SARS-CoV-2 Dual Target by RT-PCR; and DASH SARS-CoV-2/S Test (Nuclein/Molecular Diagnostics). The companies asked the FDA to revoke the authorizations, so these tests may no longer be available under EUA and could change your local testing options, but the notice states this change will not cost you extra.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in